Skip to content
stock-market — Investing — health-and-wellness — Science — Finance

Three under-the-radar biotech stocks for 2025: the reasons these investments might boost your portfolio's value

Stocks in the biotech sector might surge at the stock exchange by 2025, potentially delivering impressive returns for investors. Specifically, these three biotech stocks could thrive and be worth adding to your investment portfolio in that year.

,   and  Administrator
3 min read
Stock Exchange Rumors Point to Biotech Sector Surge in 2025, Suggesting Potential Gains for...
Stock Exchange Rumors Point to Biotech Sector Surge in 2025, Suggesting Potential Gains for Investors in Three Specific Stocks.

Three under-the-radar biotech stocks for 2025: the reasons these investments might boost your portfolio's value

The Biotech Boom: 2025's Stock Exchange Stunners

Ready to level up your portfolio in 2025? The biotech industry could be the game-changer, according to Morgan Stanley's optimistic analysts: "Despite a turbulent 2024, we remain bullish about the entire biotech arena, with a robust innovation pipeline and minimal regulatory risk." But which stocks from this exhilarating sector could set your portfolio ablaze in the coming year?

BioNTech: A Second Wind

No more sneaky secrets—BioNTech, nestled in Mainz, has been making waves. Although the demand for COVID-19 vaccines has dwindled, the stock surged at the end of 2023, bouncing back above 100 euros and even touching 120 euros at times. Investors are now shifting their focus from COVID treatments to BioNTech's thrilling oncology pipeline. The first anti-cancer drugs could hit the market as early as 2026, with pivotal studies underway and scheduled to continue in 2025. For those who look back at the corona period and notice price weaknesses, a bargain could still be up for grabs.

BioNTech (WKN: A2PSR2) ## CRISPR Therapeutics and Viking Therapeutics: Stealth Rockstars?

CRISPR Therapeutics and Viking Therapeutics might be flying under the radar for some, but they pack serious punch. While CRISPR secured the first approval for the groundbreaking gene-editing therapy, Casgevy, at the end of 2023, the therapy hasn't yet generated revenue due to its complexity. Nevertheless, the potential of Casgevy and the future applications of gene therapy is huge. With a little patience, the stock should recover from this year's decline. Compared to CRISPR, Viking is currently overvalued, with a market capitalization two billion US dollars higher. However, the treatment it is researching is nothing short of remarkable—VK2735 is a weight-loss medication that targets the pharmaceutical titans Eli Lilly and Novo Nordisk head-on. Preliminary study results are promising in both efficacy and side effects, and the market for this kind of medication is estimated to explode to hundreds of billions of US dollars within years. Viking could capture up to 21.6 billion US dollars of this market, expert forecasts suggest. Early entrants into both stocks could score a real winner. CRISPR exhibits even higher potential owing to its lackluster performance thus far.

Also read: Dividend heaven! How investors benefit and what to expect in 2025

Or: Is a market implosion on the horizon? These are the warning signs now

Disclosure Note: The publisher Boersenmedien AG's management and majority shareholder, Mr. Bernd Förtsch, has invested in the financial instruments mentioned in the publication or related derivatives that could benefit from price movements resulting from the publication.

Conflict of Interest Disclosure: The managing editor-in-chief, Mr. Frank Poepsel, holds positions in financial instruments mentioned in the publication, such as BioNTech, which could gain from any price fluctuations stemming from the publication.

On top of these picks, consider:

  1. Vertex Pharmaceuticals (VRTX): Known for its pioneering work in cystic fibrosis treatments and the recent approval of the innovative pain medication, Journavx, Vertex is poised for continued growth[1][3].
  2. Regeneron Pharmaceuticals: Often hailed as a biotech heavyweight, Regeneron continues to expand its portfolio and dominates the sector[1].
  3. Alnylam Pharmaceuticals (ALNY): With recent approvals of AMVUTTRA to treat wild-type or hereditary ATTR amyloidosis, Alnylam shows immense growth potential[2].
  4. CRISPR Therapeutics (CRSP), while not recently spotlighted, CRISPR's gene-editing technology remains a tempting investment opportunity due to its partnerships with companies such as Vertex[1].
  5. Viking Therapeutics (VKTX): Specializing in metabolic and endocrine disorders, Viking could be a worthwhile investment with its promising pipeline developments.

Other biotech stocks worth considering: Thermo Fisher Scientific, United Therapeutics, Danaher, AbbVie, Recursion Pharmaceuticals, and IQVIA, identified as stocks to watch in June 2025[3].

When investing in biotech stocks, don't forget the sector's high volatility and diversify your portfolio accordingly. Though these stocks offer immense growth potential, they also come with risks like trial failures and regulatory hurdles.

  1. The biotech industry's potential for growth in 2025 is significant, with stocks like BioNTech, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, CRISPR Therapeutics, and Viking Therapeutics presenting exciting opportunities for investors.
  2. BioNTech, despite its recent surge in stock price after a drop in demand for COVID-19 vaccines, is still considered a bargain by some investors, due to its promising oncology pipeline and potential anti-cancer drugs set to hit the market as early as 2026.
  3. CRISPR Therapeutics and Viking Therapeutics, though flying under the radar for some, have significant potential, with CRISPR securing the first approval for a gene-editing therapy and Viking researching a potentially game-changing weight-loss medication, VK2735.

Read also:

    Related

    Latest